Observational study / 2014
Elevated choline and betaine were linked to higher cardiovascular risk only when the gut-generated metabolite TMAO was also elevated.
Researchers examined fasting plasma choline and betaine levels in relation to TMAO and 3-year risk of major adverse cardiac events (MACE) in 3,903 stable cardiac patients. Higher plasma choline and betaine levels were associated with a 1.9-fold and 1.4-fold increased risk of MACE, respectively (Quartile 4 vs. 1; P < 0.01 each). After adjustment for traditional cardiovascular risk factors and hs-CRP, elevated choline (HR 1.34, 95% CI 1.03-1.74) and betaine (HR 1.33, 95% CI 1.03-1.73) remained predictive of MACE. However, neither predicted MACE risk when TMAO was added to the adjustment model, predicting future risk only when TMAO was elevated.
Shows an association, not proof of cause and effect.
- Study type
- Prospective cohort study
- Who was studied
- 3,903 sequential stable subjects undergoing elective diagnostic coronary angiography
- What was measured
- Major adverse cardiac events (death, myocardial infarction, stroke) over 3 years
THE PAPER
Prognostic value of choline and betaine depends on intestinal microbiota-generated metabolite trimethylamine-N-oxide.
Wang Z, Tang WH, Buffa JA, Fu X, Britt EB, Koeth RA, Levison BS, Fan Y, Wu Y, Hazen SL. Eur Heart J, 2014.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.